dc.contributor.author	Burns, Richéal M.
dc.contributor.author	Leal, Jose
dc.contributor.author	Wolstenholme, Jane
dc.contributor.author	O'Neill, Ciaran
dc.contributor.author	Sullivan, Frank J.
dc.contributor.author	Drummond, Frances J.
dc.contributor.author	Sharp, Linda
dc.contributor.funder	Health Research Board	en
dc.date.accessioned	2018-02-22T14:29:15Z
dc.date.available	2018-02-22T14:29:15Z
dc.date.issued	2017-01
dc.date.updated	2018-02-22T13:04:40Z
dc.description.abstract	Purpose: With one of the highest incidences across Europe and the rest of the World in 2012, the Republic of Ireland (RoI) has experienced significant increases in prostate cancer (PCa) since 1994. The main driver is the widespread use of PSA testing which is used to detect PCa. This is expected to have significant implications on resource use in the RoI. The focus of this paper was to (i) derive costs for the PCa pathway, from diagnosis to treatment, and (ii) estimate overall healthcare expenditure for PCa in the RoI. Methods: PCa incidence (ICD-10 code: C61), treatment and mortality data during 2007-2010 was obtained from the National Cancer Registry Ireland. Costs associated with diagnosis, treatment, treatment complications, clinical follow-up to year four post-diagnosis and terminal (palliative) care were estimated using sources such as survey data, Irish inpatient costs and published costs.Results: The overall estimated burden of healthcare costs associated with those diagnosed with PCa and receiving care (up to four-year post-diagnosis) or dying from PCa in 2010 was approximately (sic)45.6 million. The overall cost associated with detection, via PSA testing, for those diagnosed with PCa in 2010 (n = 3287) was (sic)366,369. Treatment costs varied considerably with the most expensive treatment being chemotherapy and radical prostatectomy (unit cost (sic)11,278 and (sic)7324, respectively). Conclusions: PCa incidence partly due to high levels of PSA testing has significant resource utilisation implications in the RoI.	en
dc.description.sponsorship	Health Research Board (HRA_HSR/2010/17)	en
dc.description.status	Peer reviewed	en
dc.description.version	Published Version	en
dc.format.mimetype	application/pdf	en
dc.identifier.citation	Burns, R. M., Leal, J., Wolstenholme, J., O' Neill, C., Sullivan, F. J., Drummond, F. J., Sharp, L. (2017) 'The burden of healthcare costs associated with prostate cancer in Ireland'. Global & Regional Health Technology Assessment, 4 (1):28-33. DOI: 10.5301/grhta.5000249	en
dc.identifier.doi	10.5301/grhta.5000249
dc.identifier.endpage	33	en
dc.identifier.issn	2284-2403
dc.identifier.issued	1	en
dc.identifier.journaltitle	Global & Regional Health Technology Assessment	en
dc.identifier.startpage	28	en
dc.identifier.uri	https://hdl.handle.net/10468/5539
dc.identifier.volume	4	en
dc.language.iso	en	en
dc.publisher	Wichtig: Open Access Journals	en
dc.relation.uri	http://www.grhta.com/article/d2c3cb15-cc4b-43af-b15b-aba4baf7821d
dc.rights	©2016 The Authors. This article is published by Wichtig Publishing and licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC-BY-NC-ND). Any commercial use is not permitted and is subject to Publisher's permissions. Full information is available at www.wichtig.com	en
dc.rights.uri	https://creativecommons.org/licenses/by-nc-nd/4.0/	en
dc.subject	Follow-up	en
dc.subject	Recommendations	en
dc.subject	Prostate cancer	en
dc.subject	Treatment costs	en
dc.title	The burden of healthcare costs associated with prostate cancer in Ireland	en
dc.type	Article (peer-reviewed)	en

The burden of healthcare costs associated with prostate cancer in Ireland

Files

Original bundle

License bundle

Collections